Equity
€231,432 ▲ 14.7%
Dr. Roelant Jan has made a profit in every financial year since 2008.
Dr. Roelant Jan
Lifetime
17 annual accounts with figures on one time axisGross marginpeak €221,941 (2024)
€187,057▼ 15.7%
Resultpeak €93,209 (2024)
€74,160▼ 20.4%
Equitypeak €231,432 (2025)
€231,432▲ 14.7%
Debts
€193,899▼ 17.9%
Staffpeak 0.3 FTE (2017)
-not published
Board1 name since 2022
1 directorROELANT Jan Luc Leonie
Documentsfilings and deeds
29-07-20262 days before the deadline
2025micro format
Gross margin from €221,941 to €187,057Dividend €44,476Equity from €201,748 to €231,432Debts from €236,252 to €193,899
Key points
from the 2025 annual accountsChecked score
95
Excellent
Financially stronger than 57% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,179 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 5.01, cash €146,419
Size: total assets €425,331
Figures for financial year 2025 (filed on 29-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 43% of them on solvency, 79% on liquidity, 46% on profitability and 58% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 34,693 companies had the same profile as Dr. Roelant Jan has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of Dr. Roelant Jan itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for Dr. Roelant Jan. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €21,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 5.01 (3.75 in 2024), above the usual 1.5. Short-term debt is 9% and cash 34.4% of total assets. 45.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 days early
2024
1 day early
2023
7 days early
2022
21 days early
2021
18 days early
2020
2 days early
2019
28 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 3 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0894325845
Company renamed from DR. ROELANT - DR. DEWAELE to Dr. Roelant Jan
Appointment: ROELANT Jan Luc Leonie (director) · Legal-form conversion: from private limited company (pre-2019) to private limited company · Director discharge: ontslagnemende bestuurder · General meeting of 05-05-2022 · Gazette deed
Incorporation
published on 31-12-2007 · Gazette deed
First establishment
Graaf de Fienneslaan 7, Edegem
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| Dr. Roelant Jan Edegem | €425,331 | €187,057 | 54.4% | - |
| Dokter B. Hautekiet Brasschaat | €444,538 | €171,374 | 96.9% | - |
| FVMS Etterbeek | €437,196 | €189,077 | 74.1% | - |
| DOKTER VAN DEN BROECK Tessenderlo-Ham | €469,128 | €184,871 | 92.6% | - |
| DOKTER GOEMAERE BART HUISARTSPRAKTIJK Kaprijke | €455,644 | €186,884 | 76.8% | - |
| Dokter Cornelissen Tongeren-Borgloon | €468,952 | €200,398 | 61.4% | - |
| DOCTEUR YALIM BOGOZ MEDECINE Ganshoren | €441,103 | €178,306 | 77.9% | - |
These companies have the same main activity as Dr. Roelant Jan: general medical practice (NACE 86210). They are comparable in size and age: total assets between €437,000 and €469,000, founded between 2005 and 2009.
Official details
Source: KBO- Status
- Active since 19-12-2007Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment unit
- 2.331.718.8602650 Edegem, since 19-12-2007
- Financial year end
- 31 December
- Peppol
- Reachable since 19-09-2025
Annual accounts 2025
- Total assets
- €425,331▼ 2.9%
- Employeeson 31-12-2025
- 4=
- Filing
- Filed on 29-07-2026, 2 days before the end of the filing period
Insights on Dr. Roelant Jan
Dr. Roelant Jan files the micro format. That format states no turnover. The gross margin rose from €3,795 in 2008 to €187,057 in 2025.
The balance sheet grew most in 2015 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Dr. Roelant Jan
- What is the company number of Dr. Roelant Jan?
- The company number of Dr. Roelant Jan is 0894.325.845. The VAT number is the same number with BE in front: BE 0894.325.845.
- Where is Dr. Roelant Jan based?
- The registered office is at Graaf de Fienneslaan 7, 2650 Edegem.Company details
- What does Dr. Roelant Jan do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of Dr. Roelant Jan?
- Dr. Roelant Jan is a private limited company (BV).
- When was Dr. Roelant Jan founded?
- Dr. Roelant Jan was founded on 19-12-2007.
- Is Dr. Roelant Jan still active?
- Yes, Dr. Roelant Jan is an active enterprise in the KBO register.
- How many employees does Dr. Roelant Jan have?
- Dr. Roelant Jan had an average of 3.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of Dr. Roelant Jan?
- The turnover in financial year 2025 is ≈ €350,000. This figure is estimated from the gross margin of €187,057 and 30 comparable companies (NACE 86210). It probably lies between €270,000 and €420,000.
- Is Dr. Roelant Jan profitable?
- In financial year 2025, Dr. Roelant Jan made a profit of €74,160.
- Where can I find the annual accounts of Dr. Roelant Jan?
- Dr. Roelant Jan filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Dr. Roelant Jan due?
- Dr. Roelant Jan must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.